Clinical-scale 10-day TCR-T cell manufacturing using IL-2/7/15 and TGF-β promotes early memory and tissue-resident-like phenotypes and robust antitumor activity in vitro - Takeaways - MDSpire

Clinical-scale 10-day TCR-T cell manufacturing using IL-2/7/15 and TGF-β promotes early memory and tissue-resident-like phenotypes and robust antitumor activity in vitro

  • By

  • Yi-Ping Shih

  • Stephan Drokin

  • Olivia Burke

  • Huayu Huang

  • Amy Leung

  • Marco Bravo-Manriquez

  • Myungkyu Jang

  • Marina S. Syrkina

  • Laura Julian

  • Nelson Sanjuan

  • Eric Tran

  • May 15, 2026

Share

  • 1

    A novel 10-day protocol for producing TCR-T cells using IL-2, IL-7, IL-15, and TGF-β enhances early memory and tissue-resident T cell phenotypes.

  • 2

    TCR-T cells generated with the cytokine cocktail exhibited increased levels of early memory and tissue-resident markers compared to those produced with IL-2 alone.

  • 3

    The enhanced TCR-T cells demonstrated superior cytotoxicity and effector cytokine production against pancreatic and colorectal cancer cell lines.

  • 4

    Clinical-scale production yielded significant quantities of TCR-T cells with comparable phenotypic and functional characteristics to small-scale experiments.

  • 5

    This innovative manufacturing method may improve the efficacy of adoptive cell therapy for solid tumors by producing TCR-T cells with favorable traits.

Original Source(s)

Clinical-scale 10-day TCR-T cell manufacturing using IL-2/7/15 and TGF-β promotes early memory and tissue-resident-like phenotypes and robust antitumor activity in vitro

  • by Yi-Ping Shih, Stephan Drokin, Olivia Burke, Huayu Huang, Amy Leung, Marco Bravo-Manriquez, Myungkyu Jang, Marina S. Syrkina, Laura Julian, Nelson Sanjuan, Eric Tran

  • May 15, 2026

Related Content

Does the Timing of Immunotherapy Administration Affect Outcomes in Advanced Cancers?

A systematic review and meta-analysis found that early time-of-day immunotherapy was associated with improved survival outcomes in patients with advanced cancers, with the association appearing to be ...

Combination Enzalutamide and Radium-223 Extends Overall Survival in Bone-Dominant mCRPC

In the final analysis of the phase III EORTC 1333/PEACE-3 trial, with a median follow-up of 58 months, the addition of radium-223 to the androgen receptor inhibitor enzalutamide significantly prolonge...

Lack of Research in Understanding the Global Population of Childhood Cancer Survivors Leads to Gaps in Care and Cures

Each year, globally, about 400,000 children and adolescents aged between 0 and 19 years are diagnosed with cancer; over 100,000 die from the disease, with most of those cases, over 80%, and deaths occ...